Back to top

Analyst Blog

Pernix Therapeutics Holdings recently announced that it has signed an agreement with the privately-held Osmotica Pharmaceuticals Corp. to market major depressive disorder (MDD) drug Khedezla.

As per the agreement, Pernix will market Khedzela Extended-Release (ER) Tablets, 50 mg and 100 mg in the U.S. Pernix has appointed approximately 90 sales professionals to promote Khedezla to desvenlafaxine prescribing physicians. Pernix and Osmotica will share profits from the sales of the drug.

We note that the U.S. Food and Drug Administration (FDA) has approved Khedezla for the treatment of major depressive disorder (MDD) in Jul 2013. The New Drug Application (NDA) for Khedezla included data from comparative bioequivalence testing against Pfizer’s (PFE - Analyst Report) Pristiq.

We remind investors that in early Mar 2013, Pernix completed the acquisition of Somaxon Pharmaceuticals, thereby adding insomnia drug Silenor to its portfolio.

Pernix expects Khedezla to represent significant promotional synergy with Silenor. The company expects to leverage its existing sale force to sell both the drugs side by side.

We note that last month Pernix appointed Doug Drysdale as its new Chief Executive Officer (CEO). Pernix also announced that a group of institutional investors led by Athyrium Capital Management have agreed to purchase $65 million aggregate principal amount of 8.00% convertible senior notes due 2019 from the company.

The notes are convertible into shares of common stock of Pernix at an initial conversion price of $3.60 per share. The appointment of Drysdale was supported by the group of institutional investors led by Athyrium Capital Management.

Pernix expects to use the capital provided from the buyout of notes for strategic acquisitions along with working capital and general corporate purposes.

Pernix currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector include Actavis, Inc. (ACT - Analyst Report), and Impax Laboratories (IPXL - Snapshot Report).  Both carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%